Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission

NCT01687387 is registered in ClinicalTrials.gov with Innate Pharma as lead sponsor.

NCT NCT01687387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01687387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission
Lead sponsor
Innate Pharma
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
November 17, 2016
Enrollment
152 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia